A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
PURPOSE OF REVIEW: Focused review highlighting ten select studies presented at the 2024 American Heart Association (AHA) Scientific Sessions. RECENT FINDING: Included studies assessed effects of intensive blood pressure control in patients with type…
CONTEXT: There is emerging evidence suggesting a possible association between glucagon-like peptide-1 receptor agonists (GLP-1 RA) and non-arteritic anterior ischemic optic neuropathy (NAION). Retrospective cohort studies supporting this association…
BACKGROUND: Renal ischemia-reperfusion injury (RIRI) is a major cause of acute kidney injury, with endothelial dysfunction playing a central role in its pathophysiology. However, the molecular mechanisms underlying endothelial damage during RIRI rema…
In addition to the classically accepted pathophysiological features of Alzheimer's disease (AD), increasing attention is paid to the role of the insulin-resistant state of the central nervous system. Glucagon-like peptide-1 receptor (GLP-1R) agonism…
Obesity and diabetes are common among patients undergoing total hip arthroplasty (THA) and are associated with adverse outcomes. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) were originally developed for glycaemic control but have recently b…
The field of antiobesity pharmacotherapy is rapidly evolving. FDA-approved medications, such as orlistat, phentermine/topiramate, bupropion/naltrexone, and liraglutide, have significantly improved weight-loss outcomes. Agents such as semaglutide and…
OBJECTIVE: A post hoc analysis of a subset of participants with visceral fat area (VFA) measurements in the STEP 6 trial was conducted to examine both the correlation between VFA and clinical parameters and the effect of semaglutide on VFA in key sub…
INTRODUCTION: Oral semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved for the treatment of type 2 diabetes mellitus (T2DM). Findings from randomized controlled trials (RCTs) and real-world studies indicate that oral semaglu…
AIM: To evaluate the efficacy and safety of semaglutide 2.4 mg versus placebo for weight management in a population of Chinese adults with overweight or obesity. MATERIALS AND METHODS: In STEP 7 (NCT04251156), a double-blind, phase 3a trial, adults f…
RATIONALE: Alcohol use disorder (AUD) remains a major public health challenge, yet effective pharmacotherapies are limited. As such, there is growing interest in repurposing medications with novel mechanisms of action. Glucagon-like peptide-1 (GLP-1)…
BACKGROUND: Hyperkalemic Periodic Paralysis (hyperPP) is an autosomal dominant genetic disorder where high extracellular potassium is associated with skeletal muscle depolarization and both flaccid muscle weakness as well as delayed muscle relaxation…
CONTEXT: Individuals with psychiatric disorders have a higher prevalence of obesity, partly because of the use of psychotropic medications. Safe and effective pharmacological interventions for weight management in this population are needed. OBJECTIV…
Amylin is a peptide hormone co-released with insulin from pancreatic β-cells during a meal and primarily serves to promote satiation. While the caudal hindbrain was originally implicated as a major site of action in this regard, it is becoming increa…
Lipidated analogues of glucagon-like peptide 1 (GLP-1) have gained enormous attention as long-acting peptide therapeutics for type 2 diabetes and also antiobesity treatment. Commercially available therapeutic lipidated GLP-1 analogues, semaglutide an…
Pasireotide (PAS), a multireceptor somatostatin analog, has been demonstrated to effectively control hormone levels, including those of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), in patients with acromegaly. However, it induces hyp…
AIMS: This study compares the therapeutic efficacy, gastrointestinal (GI) adverse event (AE) rates and the relationship between the therapeutic efficacy and GI AEs in randomized, placebo-controlled clinical trials (RCTs) of GLP-1 RAs and the dual GLP…
AIMS: To compare medication persistence and efficacy of oral and subcutaneous semaglutide, in a real-world setting. MATERIALS AND METHODS: This is a single-center, retrospective observational cohort study. Patients with type 2 diabetes mellitus (T2DM…